Is it Time for Process Excellence in Pharma R&D?
Add bookmark
Is it Time for Process Excellence in Pharma R&D?
Add bookmarkFor years pharmaceutical companies could rake in high margins on drugs that were protected by patents. But as many patents have expired or are near expiration – so much so that the industry is calling it the “patent cliff” – pharma companies are having to look much harder at how they can streamline processes in R&D to save time and money.
In this Process Perspectives podcast, Andrew Parson, VP Preclinical Drug Development at GlaxoSmithKline and Gerald Fincken, CEO of CSM Clinical trials, discuss some of the changes they’ve seen in the industry and how process excellence needs to play a more pivotal role.
[inlinead]
|
|
Have Your Say Rate this feature and give us your feedback in the comments section below |
Tags:
Andrew Parson
GlaxoSmithKline
Gerald Fincken
CSM Clinical trials
process excellence
PEX
pharma R&D
Process Perspectives
preclinical drug development
drug development
